91大神

Clinical Trial</h3>\r\n<p><b>Offered by:</b> 91大神&nbsp;Children's<br>\r\n<b>Locations: </b>Delaware Valley and Jacksonville, Florida</p>\r\n<h3>Trial Name</h3>\r\n<p>A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC#&nbsp;683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma</p>\r\n<h3>What is the trial about?<br>\r\n</h3>\r\n<p>Children's Oncology Group&nbsp;is testing 2 investigational drug combinations to find a new therapy for treating relapsed or refractory neuroblastoma.</p>\r\n<h3>Who can participate?<br>\r\n</h3>\r\n<p>Children who have been diagnosed with relapsed or refractory neuroblastoma will be asked to be in this study.</p>\r\n<h3>What is involved?</h3>\r\n<ul>\r\n<li>Children in this clinical trial may get treatment on this study for about 1 year. We would like to continue to find out about your child's health every year for about 5 years after he/she enters this study.</li>\r\n<li>Some participants will get the drug temsirolimus and some will get ch14.18 and GM-CSF. The rest of the treatment will be the same.&nbsp;</li>\r\n</ul>\r\n"}} id=text-8c51df2f5d class=cmp-text>

Clinical Trial

Offered by: 91大神听Children's
Locations: Delaware Valley and Jacksonville, Florida

Trial Name

A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC#听683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma

What is the trial about?

Children's Oncology Group听is testing 2 investigational drug combinations to find a new therapy for treating relapsed or refractory neuroblastoma.

Who can participate?

Children who have been diagnosed with relapsed or refractory neuroblastoma will be asked to be in this study.

What is involved?

• Children in this clinical trial may get treatment on this study for about 1 year. We would like to continue to find out about your child's health every year for about 5 years after he/she enters this study.
• Some participants will get the drug temsirolimus and some will get ch14.18 and GM-CSF. The rest of the treatment will be the same.听

<strong>Trial Name: </strong>A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC#&nbsp;683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma</p>\r\n<p><strong>ANBL#:</strong> 1221</p>\r\n"}} id=text-aff71e3a6b class=cmp-text>

Trial Name: A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC#听683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma

ANBL#: 1221